Lancet Glob Health. 2014 Apr;2(4):e209-15. doi: 10.1016/S2214-109X(14)70018-X.
Studies of HIV-serodiscordant couples in stable sexual relationships have provided convincing evidence that antiretroviral therapy can prevent the transmission of HIV. We aimed to quantify the preventive effect of a public-sector HIV treatment and care programme based in a community with poor knowledge and disclosure of HIV status, frequent migration, late marriage, and multiple partnerships. Specifically, we assessed whether an individual's hazard of HIV acquisition was associated with antiretroviral therapy coverage among household members of the opposite sex.
In this prospective cohort study, we linked patients' records from a public-sector HIV treatment programme in rural KwaZulu-Natal, South Africa, with population-based HIV surveillance data collected between 2004 and 2012. We used information about coresidence to construct estimates of HIV prevalence and antiretroviral therapy coverage for each household. We then regressed the time to HIV seroconversion for 14,505 individuals, who were HIV-uninfected at baseline and individually followed up over time regarding their HIV status, on opposite-sex household antiretroviral therapy coverage, controlling for household HIV prevalence and a range of other potential confounders.
2037 individual HIV seroconversions were recorded during 54,845 person-years of follow-up. For each increase of ten percentage points in opposite-sex household antiretroviral therapy coverage, the HIV acquisition hazard was reduced by 6% (95% CI 2–9), after controlling for other factors. This effect size translates into large reductions in HIV acquisition hazards when household antiretroviral therapy coverage is substantially increased. For example, an increase of 50 percentage points in household antiretroviral therapy coverage (eg, from 20% to 70%) reduced the hazard of HIV acquisition by 26% (95% CI 9–39).
Our findings provide further evidence that antiretroviral therapy significantly reduces the risk of onward transmission of HIV in a real-world setting in sub-Saharan Africa. Awareness that antiretroviral therapy can prevent transmission to coresident sexual partners could be a powerful motivator for HIV testing and antiretroviral treatment uptake, retention, and adherence.
Wellcome Trust and National Institute of Child Health and Human Development (US National Institutes of Health).
在稳定性关系的 HIV 血清不一致的夫妇中进行的研究提供了令人信服的证据,表明抗逆转录病毒疗法可以预防 HIV 的传播。我们旨在量化在一个对 HIV 知之甚少且披露情况不佳、频繁迁移、晚婚和多伴侣关系的社区中开展的公共部门艾滋病毒治疗和护理计划的预防效果。具体而言,我们评估了个体获得 HIV 的风险是否与异性家庭成员接受抗逆转录病毒疗法的覆盖率有关。
在这项前瞻性队列研究中,我们将南非夸祖鲁-纳塔尔省一个公共部门艾滋病毒治疗计划的患者记录与 2004 年至 2012 年间收集的基于人群的艾滋病毒监测数据相关联。我们使用关于共同居住的信息来构建每个家庭的 HIV 流行率和抗逆转录病毒疗法覆盖率的估计值。然后,我们根据异性家庭抗逆转录病毒疗法的覆盖率,对 14505 名个体的时间进行回归分析,这些个体在基线时未感染 HIV,并且随着时间的推移分别对其 HIV 状况进行了随访,控制了家庭 HIV 流行率和一系列其他潜在混杂因素。
在 54845 人年的随访期间,记录了 2037 例个体 HIV 血清转换。在控制其他因素后,异性家庭抗逆转录病毒疗法覆盖率每增加 10 个百分点,HIV 获得风险就降低 6%(95%CI 2-9)。当家庭抗逆转录病毒疗法覆盖率显著增加时,这种效果大小会导致 HIV 获得风险的大幅降低。例如,家庭抗逆转录病毒疗法覆盖率增加 50 个百分点(例如,从 20%增加到 70%)可使 HIV 获得风险降低 26%(95%CI 9-39)。
我们的研究结果进一步证明,在撒哈拉以南非洲的现实环境中,抗逆转录病毒疗法可显著降低 HIV 传播的风险。了解抗逆转录病毒疗法可以预防传播给共同居住的性伴侣,这可能是促使 HIV 检测和抗逆转录病毒治疗的接受、保留和坚持的有力动力。
惠康信托基金会和美国国立儿童健康与人类发展研究所(美国国立卫生研究院)。